dennis mccain
  • Home
  • Investing
    • Best Ideas
    • New Highs
    • Dividend Increases
    • Dividend Kings
    • Div Aristocrats
    • Div Champions
    • Business Dev Cos
    • Monthly Dividends
  • Options
    • Weekly Options
  • Photography
    • Photography Gear
    • Hiking Trails
  • Biography
  • Index
  • Contact Me

Investing

Ideas and Strategies on Investing.

Previous Articles

Novocure

6/20/2017

2 Comments

 
Novocure may have finally found a bottom earlier this year. Since April the stock has doubled and it's starting to look like there's a lot more room to go even higher. Novocure has developed a fourth method of treating cancers that can augment or replace surgery, radiation therapy and chemotherapy. The idea of tumor treating fields may one day be the primary method of treating cancers until a cure for cancer can be found. 

This could be one of the most important medical devices ever created for the treatment of cancers and could be in wide use in the next few years. And if that's true, I'd like to be one of their shareholders. Therefore I'll be starting a small position in this company and see where it goes. 


​NovoCure Limited
engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) for the treatment of solid tumors. The company markets its proprietary therapy, TTFields delivery system under the Optune name for use as a monotherapy treatment for adult patients with glioblastoma brain cancer. It is also involved in conducting clinical trials for the use of TTFields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer, and mesothelioma. The company markets its products in the United States, Germany, Switzerland, Japan, and other countries. NovoCure Limited was founded in 2000 and is based in Saint Helier, the Channel Islands.
(Summary) (Company) (Chart)
19 June 2017
Price $15.80
1yr Target $20.40
Analysts 5
Dividend $0.00
Payout Ratio ---

1yr Cap Gain 29.11%
Yield 0.00%
1yr Tot Return 29.11%

P/E ---
PEG ---
Beta ---
​
EPS (ttm) $-1.33
EPS next yr $-0.26
Forward P/E ---
EPS next 5yr 60.00%
1yr Price Support $---

Market Cap $1.40 Bil
Revenues $104.70 Mil
Earnings $-114.50 Mil
Profit Margin ---

Quick Ratio 6.80
Current Ratio 7.60
Debt/Equity 0.75


1yr RevGR 288.48%
3yr RevGR ---
5yr RevGR ---

1yr EarnGR ---
3yr EarnGR ---
5yr EarnGR ---

1yr DivGR ---
3yr DivGR ---
5yr DivGR ---

ROA -42.10%
ROE -74.30%


Picture
Novocure Revenue Growth
Picture
Novocure Weekly Chart

​In 2000, Yoram Palti, founder and professor emeritus of physiology and biophysics at the Technion — Israel Institute of Technology, sought to leverage his expertise in biophysics to develop a new way to treat solid tumor cancers that would destroy tumor cells while sparing healthy tissue and avoiding many of the life-altering side effects of existing cancer therapies.
He set up a laboratory in his basement to explore the potential of electric fields as a treatment for solid tumors.

Professor Palti founded Novocure to provide patients with a new cancer treatment based on his hypothesis, since proven, that low-intensity, alternating electric fields, when applied at specific frequencies, can disrupt cancer cell division and cause cancer cell death. This innovative treatment,   Tumor Treating Fields, or TTFields, is a completely different approach to cancer therapy.

Optune was launched (their TTFields delivery system for glioblastoma) in the United States for the treatment of recurrent glioblastoma in 2011. In October 2015, the Company received FDA approval to market and sell Optune for the treatment of adult patients with newly diagnosed GBM in combination with temozolomide.  

The science of TTFields has the potential to extend beyond GBM. The Company has five ongoing or completed phase 2 pilot trials for brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer and mesothelioma. They presented their phase 2 pilot data in pancreatic and ovarian cancers at their research and development day on Dec. 12, 2016. In 2016, they began their phase 3 pivotal trial in brain metastases originating from non-small cell lung cancer. Internationally, more than 20 institutions are studying the effects of TTFields in cancer treatment.

The company began with a patient-forward approach that continues to drive their mission today. With more than 15 years of research and many significant milestones, they have established themselves as an innovator in oncology dedicated to improving the lives of cancer patients.
​

2 Comments
David
8/13/2017 03:43:23 am

I think they are a great company

Reply
Dennis McCain link
8/13/2017 09:28:50 am

So do I.

Respectfully,
Dennis McCain

Reply



Leave a Reply.

    Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

    Picture

    Author

    I am an Individual Investor with specific interest in long term growth and then enhancing my returns with income from dividends and derivatives. I don't recommend stocks to anyone (it's a good way to lose friends) and no one reading this should misinterpret my blog as a recommendation for any type of investment. I am writing this solely for myself and my kids.


    RSS Feed


    Picture
    Top 100 Blogs for Dividend Investors

    Picture
    Follow Me on StockTwits!



    Dividend Growth Stocks
    Dividend Growth Investor


    Picture
    I'm on Seeking Alpha too!

    Archives

    August 2018
    July 2018
    June 2018
    May 2018
    April 2018
    March 2018
    February 2018
    January 2018
    December 2017
    November 2017
    October 2017
    September 2017
    August 2017
    July 2017
    June 2017
    May 2017
    April 2017
    March 2017
    February 2017
    January 2017
    December 2016
    November 2016
    October 2016
    September 2016
    August 2016
    July 2016
    June 2016
    May 2016
    April 2016
    March 2016
    February 2016
    January 2016
    December 2015
    November 2015
    October 2015
    September 2015
    August 2015
    July 2015
    June 2015
    May 2015
    April 2015
    March 2015
    February 2015
    January 2015
    December 2014
    November 2014
    October 2014
    September 2014
    August 2014
    July 2014
    June 2014
    May 2014
    April 2014
    March 2014
    February 2014
    January 2014
    December 2013
    November 2013
    October 2013
    September 2013
    August 2013


    ADDITIONAL RESOURCES:
    4 Month INDU Chart
    Dividend Ex-Dates
    Bidness Etc
    SharpCharts Voyeur
    StockCharts.com

    FINVIZ
    Seeking Alpha
    BDC Reporter
    Roadmap2Retire
    DivHut
    Dividend Growth Investor

    Dividend Yield

    Stock Market Mentor
    Chart Swing Trader
    Dividend Announcements
    IBD TV
    Stocks to Watch Today
    Dividend Detective

    DISCLAIMER
     I am not a licensed investment adviser, and I am not providing investment advise for you on this site. Please consult with an investment professional before you invest your money. Any opinion expressed here should not be treated as investment advice. I am not liable for any losses suffered by any party because of data or information published on this blog. Past performance is not a guarantee of future performance. Unless your investments are FDIC insured, they may decline in value.

    Picture
Powered by Create your own unique website with customizable templates.